The Adaptive Trial: AI in Bioinformatics and Clinical Research

Clinical research AI can help a team find protocol contradictions, prioritize records for screening, reproduce a bioinformatics pipeline, or detect an unusual data pattern. None of those outputs establishes that a participant is eligible, an adverse event is related, an endpoint is met, or a product is safe and effective. Those conclusions belong to qualified investigators, statisticians, ethics bodies, sponsors, and regulators under the applicable protocol and law.

The operating boundary is therefore non-negotiable: AI trial support is not medical judgment, trial authorization, or regulatory approval. A model may organize and test evidence. It may not diagnose a person, replace informed consent, alter a prespecified analysis without governance, or present its own confidence as agency acceptance. This article describes system design and research operations, not medical advice.

1. Anchor every use case to the approved protocol

Create a controlled representation of objectives, population, arms, interventions, visits, assessments, endpoints, eligibility criteria, safety reporting, analysis populations, and amendment history. Keep the signed protocol and approved amendments as authoritative records; a structured copy is an operational aid. Each machine-readable rule should cite its source section and effective version.

The ClinicalTrials.gov protocol registration data definitions show how identifiers, design, outcomes, eligibility, oversight, responsible parties, history, and individual-participant-data sharing are represented for registry submission. They are registration definitions, many linked to U.S. regulatory requirements, not a complete protocol template or a judgment that a trial is compliant.

Block an assistant from mixing versions across sites. If amendment 3 changes an inclusion threshold, the screening tool must know the site approval date and participant-consent context before applying it. Unresolved contradictions become human queries; they are never silently reconciled by a language model.

2. Map decision rights across the trial

The sponsor owns defined responsibilities and oversight; the investigator protects participants and makes clinical decisions; data management maintains controlled trial data; biostatistics owns prespecified analysis; monitors verify processes and evidence; ethics committees and regulators exercise their mandates. Vendors support these roles but do not inherit them because they operate a model.

Create a RACI matrix for every AI output. A cohort-feasibility estimate may be informational. A suggested participant match requires trained review against source records. A possible safety signal requires immediate routing under the safety plan. A proposed endpoint change requires protocol, statistical, ethical, and regulatory governance. The workflow should make escalation easier than bypass.

3. Build lineage from specimen and observation to analysis

Assign stable identifiers to participant, encounter, specimen, aliquot, assay run, image, device, site, laboratory, dataset, and analysis. Record collection and processing times, units, reference ranges, instrument and reagent lot, calibration, transformation, quality-control result, and reason for exclusion. Separate raw, derived, corrected, and adjudicated values.

For omics data, version the reference genome, annotation, aligner, parameters, feature definitions, normalization, and statistical environment. Package code and immutable configuration with the result. A biomarker score without the exact pipeline and sample chain is not reproducible evidence. Never allow a notebook’s “latest” dependency to redefine a locked analysis.

4. Design patient matching as review support

A matching system can translate eligibility criteria into candidate queries and highlight evidence in the health record. It must represent time windows, negation, uncertainty, missingness, and criterion dependencies. “No documented condition” is not the same as “condition absent,” and a problem-list code is not always a confirmed diagnosis.

Return candidate, criterion-by-criterion evidence, source timestamp, and unresolved items to authorized study staff. Require source verification, investigator confirmation where applicable, and the full consent process before enrollment. Do not contact a candidate or expose research interest through an insecure channel merely because a model generated a high score. AI in healthcare provides a broader view of clinical workflow boundaries.

5. Protect representation and equitable access

Historic site data reflect referral patterns, insurance access, geography, digital access, language availability, and prior inclusion choices. A model trained on enrolled participants can reproduce those barriers while appearing statistically accurate. Evaluate the funnel from potentially eligible population through query, outreach, screening, consent, enrollment, retention, and completion.

Measure missingness and error by site and relevant demographic or access group where lawful and scientifically appropriate. Provide translated materials and non-digital contact routes; do not use digital activity as a proxy for adherence. Document when a feature such as travel distance or prior appointment history is used and how it could exclude people facing structural constraints. For population-level considerations, see AI in public health and epidemiology.

6. Treat biomarker discovery as hypothesis generation

Separate exploratory discovery, internal validation, locked validation, and clinical qualification. Use subject-level splits that prevent samples from the same person entering both training and test sets. Prevent batch, site, instrument, slide, or time leakage. Account for multiplicity and class imbalance, and report confidence intervals rather than a single discrimination score.

Ask whether the model learns biology or a laboratory artifact. Test performance across acquisition platforms, sites, disease stages, and relevant populations. Predetermine the threshold before final validation. A compelling retrospective association is not automatically a predictive biomarker, a companion diagnostic, or a basis for patient management.

7. Keep adaptive methods prespecified and governed

Adaptive designs can change allocation, sample size, dose, population, or stopping according to a prospectively defined rule. An AI forecast may support simulation or operational planning, but it must not improvise a design adaptation from accumulating unblinded data. Preserve firewalls, access controls, simulation code, decision thresholds, and the body authorized to act.

Use statisticians and regulatory experts to test type I error, operating characteristics, estimand implications, missing-data behavior, and sensitivity to model drift. Any departure from the approved plan needs formal assessment and documentation. “The algorithm learned” is not an acceptable reason to erase prespecification.

8. Validate digital technologies as fit for purpose

The FDA’s final guidance on digital health technologies for remote data acquisition in clinical investigations addresses selection, verification, validation, usability, data management, and participant considerations. It is U.S. FDA guidance with a defined scope, not approval of a particular wearable, model, or endpoint.

Document the context of use, measured concept, target population, operating environment, sampling frequency, firmware, connectivity, failure states, and acceptable missingness. Confirm time synchronization and distinguish “device not worn,” “transmission failed,” and “valid zero.” Changes to firmware or an embedded algorithm can alter measurement properties and require impact assessment.

9. Distinguish final guidance from AI draft guidance

The FDA’s January 2025 document on AI used to support regulatory decision-making for drugs and biological products is labeled draft guidance and “not for implementation.” It proposes a risk-based credibility-assessment framework tied to a model’s context of use. It must not be quoted as final agency policy or as a preapproval certificate.

Maintain a guidance register with issuing body, title, version, status, date, jurisdiction, product scope, and internal interpretation owner. When a draft changes, perform a gap assessment rather than silently updating a checklist. Meeting minutes and agency correspondence for a specific program remain distinct evidence; a public draft cannot predict an agency’s decision.

10. Preserve Good Clinical Practice controls

The EMA page for ICH E6 Good Clinical Practice records documents and regional status for ICH E6 revisions, including the continuing evolution of R3 materials. Adoption and effective dates can differ by annex and region. Teams must verify which version is legally or procedurally applicable to each trial rather than treating “R3” as a single global switch.

Apply quality by design to factors critical to participant protection and reliable results. Validate computerized systems proportionately, control access, maintain attributable audit trails, investigate material deviations, and preserve records. AI observability logs supplement—not replace—trial master file, source, safety, data-management, and statistical records.

11. Govern data sharing and secondary use

The NIH Data Management and Sharing Policy overview describes planning, budgeting, managing, and sharing scientific data for research within its NIH funding scope. It does not mean every participant-level record can be made public. Consent, privacy, tribal or community agreements, intellectual property, data-use terms, and repository controls still matter.

Create dataset passports that state purpose, population, consent limitations, permitted users, de-identification method, linkage risk, transformations, quality caveats, and withdrawal handling. A model vendor must not reuse trial prompts or data for training unless contracts, consent, policy, and law permit it. Test exports and logs for residual identifiers and rare combinations.

12. Build an evidence and audit architecture

Separate electronic data capture, source systems, laboratory and imaging repositories, randomization, safety, document management, analysis environment, model gateway, and workflow orchestration. Use least-privilege service identities and approved data transfers. Freeze the model artifact, code, prompt, retrieval corpus, feature specification, and dependency set for each material analysis or decision-support release.

An evidence object should connect input records, preprocessing, validation state, output, reviewer, decision, timestamp, and superseding event. AI audit evidence and assurance explains how this chain supports reconstruction. Hashes prove file integrity, not scientific validity; a complete log can still document a flawed method.

13. Monitor safety without delegating causality

Models can triage incoming narratives, identify duplicates, map terms, or detect statistical disproportionality. They cannot make the investigator’s clinical assessment, determine causality autonomously, or delay expedited reporting while waiting for a score. Configure safety queues to fail open to trained review when a model or integration is unavailable.

Test recall for serious, unexpected, pregnancy, device, and special-situation narratives; include spelling errors, multiple languages, negation, and attachments. Keep original text alongside structured coding. Monitor queue age, unreviewed cases, duplicate merges, model changes, and downstream reconciliation with clinical and safety databases.

14. Evaluate scientific and operational performance

Evaluation must match the context of use. For screening, measure criterion-level precision and recall, candidates missed, time to verified eligibility, and representativeness through the funnel. For biomarkers, report discrimination, calibration, clinical utility assumptions, subgroup uncertainty, external validation, and leakage tests. For document assistants, measure citation correctness and omission of material exceptions.

Operational indicators should include:

• protocol deviations caused or prevented by the tool;
• safety-case recall, triage time, and manual backlog;
• data-query rate, unresolved discrepancies, and correction latency;
• uptime, stale-source detection, and manual-mode performance;
• reviewer override, reason, and subsequent adjudication;
• privacy, access, consent, and data-use incidents;
• reproducibility from raw input to locked output;
• site workload and participant burden, not only sponsor cycle time.

A lower screening workload is not a benefit if eligible people disappear from the funnel. A higher model score is not meaningful without a prespecified comparator and uncertainty.

15. Roll out through evidence gates

Begin with non-consequential tasks: controlled search, document comparison, code-list assistance, and reproducibility checks. Next run screening or safety triage in silent mode against adjudicated cases. Then offer cited suggestions to trained users without changing source data. Advance to bounded workflow integration only after validation, security, privacy, quality, statistical, clinical, and regulatory owners approve the context of use.

Every stage needs a protocol-aligned validation plan, acceptance thresholds, change control, incident response, site training, participant-impact review, rollback, and periodic revalidation. Reassess after amendments, population changes, new sites, firmware changes, data shifts, or model updates. Freeze or retire a system when its evidence no longer matches the use.

Source notes

Sources were reviewed on July 30, 2026. The FDA remote-data-acquisition guidance is final and scoped to digital health technologies in clinical investigations. The January 2025 FDA AI document is draft guidance, not for implementation, and must not be represented as final policy. ClinicalTrials.gov definitions support registration fields but do not replace a protocol or regulatory assessment. The NIH policy applies within its stated funding and data scope. ICH E6 materials have region- and document-specific adoption and effective dates; the cited EMA status page should be checked again for each program. Qualified clinical, statistical, quality, ethics, privacy, security, and regulatory professionals must determine the requirements for a real trial.